Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Squamous Cell Carcinoma: early-phase trial registry
17 of 48 indexed Squamous Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #297 of 28,707 conditions by registered trial count.
48 US clinical trials · 17 currently recruiting · #297 of 28,707 conditions by registered trial count
Squamous Cell Carcinoma: 48 US clinical trials tracked, 17 recruiting.
Squamous Cell Carcinoma is the subject of 48 registered US clinical trials on ClinicalTrials.gov, 17 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 32 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 3 of these trials.
Enrollment posture brief
Registry condition squamous-cell-carcinoma
OPEN 17 | RECR 35% | LATE 0 | EARLY 32 | RANK #297 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Pneumonia (35% recruiting · 48 trials)
Squamous Cell Carcinoma lists 17 open slots (35% of 48 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Squamous Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Squamous Cell Carcinoma is recruiting below its size-band peers.
17 of 48 indexed trials (35.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Squamous Cell Carcinoma trials is spread across many organizations.
H. Lee Moffitt Cancer Center and Research Institute accounts for 3 of 48 trials (6.3%). 38 distinct sponsors appear on at least one study for this condition label.
-
Most Squamous Cell Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 45 among the 48 trials that report a genuine target (sentinel values excluded). 36 of those (75%) plan for fewer than 100 participants.
-
Squamous Cell Carcinoma research is mostly interventional.
39 interventional and 9 observational studies make up this index (81.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
48 total, page 1 of 1
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Diwakar Davar
NCT07223424
Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction
Matthew Spector
NCT06831149
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Christopher Wilke
NCT02128906
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
Bruce Robinson, MD
NCT07010692
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
Indiana University
NCT05108090
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT02133196
Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain
New York University
NCT07095608
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT07209189
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Alain Algazi
NCT03708224
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
M.D. Anderson Cancer Center
NCT05027633
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
ImmVira Pharma Co.
NCT04370587
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
Ryan Carey
NCT06747390
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
M.D. Anderson Cancer Center
NCT05681039
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05070403
Toripalimab With Chemotherapy for Sinus Cancer
Glenn J. Hanna
NCT06940180
Raman Spectroscopy and Skin Cancer
Renee Farrell
NCT06384924
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
Stanford University
NCT06731933
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
National Cancer Institute (NCI)
NCT03952585
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
Abramson Cancer Center at Penn Medicine
NCT03729518
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
University of Oklahoma
NCT05863052
Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia
Children's Hospital Medical Center, Cincinnati
NCT03476330
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
Thomas Jefferson University
NCT03854032
Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of Disease
Memorial Sloan Kettering Cancer Center
NCT05048459
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
Memorial Sloan Kettering Cancer Center
NCT05574101
Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
Diwakar Davar
NCT04808999
Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC
H. Lee Moffitt Cancer Center and Research Institute
NCT06137274
Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.
Sherrif Ibrahim
NCT05858229
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck
University of Maryland, Baltimore
NCT04150900
DERM US and EU Validation Study
Skin Analytics Limited
NCT05126173
Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer
University of Minnesota
NCT01089803
Electronic Brachytherapy for the Treatment of NMSC
Xoft
NCT01016899
Does Cryofixation of Skin Specimens Affect Quality of Subsequent Formalin Fixed Paraffin Embedded H and E Histology
Abramson Cancer Center at Penn Medicine
NCT01540695
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
Leap Therapeutics
NCT02013154
A Phase 1 Study in Participants With Advanced Cancer
Eli Lilly and Company
NCT01115790
Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery
Mayo Clinic
NCT00578214
Pembrolizumab in Combination With CRT for LA-SCCHN
Sanford Health
NCT02586207
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
NewLink Genetics Corporation
NCT00073398
Reflectance Confocal Microscopy of Wounds During Moh's Surgery: Feasibility Testing of a Mosaicing Algorithm for Intraoperative Imaging of Cancer Margins
Memorial Sloan Kettering Cancer Center
NCT01872130
Photochemical Tissue Bonding
Massachusetts General Hospital
NCT00586040
A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer
National Cancer Institute (NCI)
NCT00001442
De-Escalation Therapy for Human Papillomavirus Negative Disease
University of Chicago
NCT03944915
Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Dana-Farber Cancer Institute
NCT00139230
Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer
Emory University
NCT01526486
PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients
University of Wisconsin, Madison
NCT03342378
Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00195299
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT03758781
Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma
The University of Texas Health Science Center at San Antonio
NCT01592721
Fluorine F 18 EF5 Positron Emission Tomography in Assessing Hypoxia in Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Head or Neck Squamous Cell Cancer of the Oral Cavity, Oropharynx, and Larynx
Abramson Cancer Center at Penn Medicine
NCT01020097
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 21 |
Top Sponsors
Named interventions
Most-linked intervention names on Squamous Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Squamous Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Squamous Cell Carcinoma page
48 registered trials, 17 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 17 Squamous Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- H. Lee Moffitt Cancer Center and Research Institute sponsors the most Squamous Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See H. Lee Moffitt Cancer Center and Research Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Squamous Cell Carcinoma condition card totals 48 registered trials; most-linked intervention Cisplatin; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.